Kininogen Antibody (236006) [Alexa Fluor® 750]

• Reactivity: Hu
• Applications: WB, IP
• Clone: 236006
• Clonality: Monoclonal
• Host: Mouse
• Conjugate: Alexa Fluor 750

Kininogen Antibody (236006) [Alexa Fluor® 750] Summary

• Immunogen: Mouse myeloma cell line NS0-derived recombinant human Kininogen
  Gln19-Ser644 (Ile581Thr) (predicted)
  Accession # P01042.2
• Specificity: Detects human Kininogen Light Chain in direct ELISAs and Western blots. In Western blots, it reacts with the full length (amino acids 19‑644) and two forms of the light chain starting at amino acids 390 and 438, respectively, and does not react
• Isotype: IgG2b
• Clonality: Monoclonal
• Host: Mouse
• Purity Statement: Protein A or G purified

Applications/Dilutions

• Dilutions:
  • Immunoprecipitation
  • Western Blot

Packaging, Storage & Formulations

• Storage: Protect from light. Do not freeze. 12 months from date of receipt, 2 to 8 °C as supplied
• Buffer: Supplied 0.2mg/ml in 1X PBS with RDF1 and 0.09% Sodium Azide

Notes

This product is produced by and ships from R&D Systems, Inc., a Bio-Techne brand.

Alternate Names for Kininogen Antibody (236006) [Alexa Fluor® 750]

• alpha 2-thiol Proteinase Inhibitor
• BDK
• BDK;BK;HAE6;HK;HMWK;Kininogen-1;KNG;KNG1
• Kininogen
• KNG1

Background

Kininogen, also known as alpha 2-thiol proteinase inhibitor, is a multi-function protein. There are two alternatively spliced forms, designated as the high molecular weight (HMW) and low MW (LMW) forms (1). The HMW form is synthesized as a 644 amino acid (aa) precursor with a signal peptide (aa 1‑18). The mature chain (aa 19‑644) is further processed into the heavy (aa 19‑380) and the light (aa 390‑644) chains. The active peptide bradykinin (aa 381‑389) is released, which has a variety of functions including muscle contraction, hypotension and inflammation. The heavy chain consists of three cystatin-like domains, which are responsible for inhibiting cysteine proteases. The light chain consists of a His-rich domain, which is associated with the clotting activity. In comparison to the HMW form, the LMW Kininogen (427 aa) has the same sequence in its heavy chain and bradykinin, but a different sequence in its light chain (aa 402‑427). The LMW form is not involved in blood clotting.

Limitations

This product is for research use only and is not approved for use in humans or in clinical diagnosis. Primary Antibodies are guaranteed for 1 year from date of receipt.